Olmita (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil is an angiotensin II receptor blocker (ARB). It selectively blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and stimulating aldosterone release. This results in relaxed blood vessels and reduced fluid retention, which together lower systemic blood pressure.

The dose of Olmita is individualized by a prescriber based on the patient’s blood‑pressure level, response to therapy, and any co‑existing medical conditions. Healthcare professionals determine the appropriate strength and dosing schedule, which is typically taken once daily.

Olmita is contraindicated in pregnancy because the ARB component can cause fetal harm, especially in the second and third trimesters. Breastfeeding is not recommended without medical advice, as the drugs may pass into milk and affect the infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To request Olmita, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olmita combines an ARB (olmesartan) with a calcium‑channel blocker (amlodipine), offering dual‑mechanism blood‑pressure control in a single tablet. Compared with monotherapy, the combination can provide greater efficacy, simplify dosing, and improve adherence. Alternatives may include ACE‑inhibitor/CCB combos or separate tablets, but the fixed‑dose format reduces pill burden.

Olmita tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or extreme temperatures.

Olmita is taken orally, usually once daily, with or without food. Swallow the tablet whole with a glass of water. Patients should follow the prescribing clinician’s instructions regarding timing and any specific dietary considerations.

The most serious risks include angio‑edema, severe hypotension, significant kidney function decline, and hyper‑kalemia. Patients should be educated to seek immediate medical attention if they experience rapid swelling of the face, lips or throat, fainting, or any signs of allergic reaction.

Olmita should not be used by individuals who are pregnant, have known hypersensitivity to olmesartan, amlodipine or any excipients, or are currently receiving another ARB, ACE inhibitor, or direct renin inhibitor. Caution is also advised for patients with severe renal or hepatic impairment.